

中国产学研合作促进会科技创新奖公示情况表

- 一、奖项类型：创新成果奖
- 二、项目名称：肺癌精准治疗关键技术创新与应用
- 三、主要完成单位：中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所）、四川科伦博泰生物医药股份有限公司、湖南省肿瘤医院
- 四、主要完成人：张力、葛均友、方文峰、杨云鹏、金小平、赵洪云、黄岩、罗永忠、洪少东、周华强
- 五、代表性知识产权

序号	知识产权具体名称	国家（地区）	授权号	授权日期	权利人	发明人
1	一种耐奥希替尼的人非小细胞肺癌细胞株 H1975/OR 及其应用	中国	ZL202010506000.4	2023-06-30	中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所）	张力;潘慧;袁泽;占建华;黄岩
2	生物活性物偶联物及其制备方法和用途	中国	ZL201880069543.5	2021-10-22	四川科伦博泰生物医药股份有限公司	蔡家强 ;宋帅;薛彤彤;肖亮;邓汉文;田强;汪静;刘登念;刘立平;喻海旻;杨周宁;曹旭;钟国庆;王利春;王晶翼
3	生物活性物偶联物及其制备方法和用途	香港	HK40020572	2022-03-18	四川科伦博泰生物医药股份有限公司	-
4	生物活性物偶联物及其制备方法和用途	中国	ZL202111114512.7	2025-02-18	四川科伦博泰生物医药股份有限公司	蔡家强 ;宋帅;薛彤彤;肖亮;邓汉文;田强;汪静;刘登念;刘立平;喻海旻;杨周宁;曹旭;钟国

						庆;王利春;王晶翼
5	生物活性物 偶联物及其 制备方法和 用途	中国	ZL202111 113700.8	2024-10- 25	四川科伦博泰 生物医药股份 有限公司	蔡家强 ;宋帅; 薛彤彤;肖亮;邓 汉文;田强;汪 静;刘登念;刘立 平;喻海旻;杨周 宁;曹旭;钟国 庆;王利春;王晶 翼
6	生物活性物 偶联物及其 制备方法和 用途	中国	ZL202411 350546.X	2025-04- 25	四川科伦博泰 生物医药股份 有限公司	蔡家强 ;宋帅; 薛彤彤;肖亮;邓 汉文;田强;汪 静;刘登念;刘立 平;喻海旻;杨周 宁;曹旭;钟国 庆;王利春;王晶 翼
7	生物活性物 偶联物及其 制备方法和 用途	日本	JP744699 3	2024-03- 11	四川科伦博泰 生物医药股份 有限公司	-
8	生物活性物 偶联物及其 制备方法和 用途	美国	US119705 06	2024-04- 30	四川科伦博泰 生物医药股份 有限公司	蔡家强 ;宋帅; 薛彤彤;肖亮;邓 汉文;田强;钟国 庆;王利春;王晶 翼
9	喜树碱衍生 物及其水溶 性前药、包 含其的药物 组合物及其 制备方法和 用途	中国	ZL202080 006538.7	2024-07- 05	四川科伦博泰 生物医药股份 有限公司	李德亮;田强;宋 帅;连炜;蔡家 强;王利春;王晶 翼

六、代表性论文

序号	论文题目	所有作者（通讯作者请标注*）	期刊名称	年份、卷期及页码	影响因子	他引次数
1	Sacituzumab tirumotecan versus docetaxel for previously treated EGFR-mutated advanced non-small cell	Wenfeng Fang, Xingya Li, Qiming Wang, Xiangjiao Meng, Wei Zheng, Longhua Sun, Wenxiu Yao, Wu Zhuang, Yun Fan, Minglei Zhuo, Yongzhong Luo, Zhiye Zhang, Xia Song, Runxiang Yang, Jiacheng Yang, Xiaoping Jin, Yina Diao,	BMJ	2025:389:e085680.	42.7	1

	lung cancer: multicentre, open label, randomised controlled trial	Junyou Ge, Li Zhang*				
2	Ivonescimab Plus Chemotherapy in Non-Small Cell Lung Cancer With EGFR Variant: A Randomized Clinical Trial	Wenfeng Fang, Yuanyuan Zhao, Yongzhong Luo, Runxiang Yang, Yan Huang, Zhiyong He, Hui Zhao, Mingjun Li, Kai Li, Qibing Song, Xiaobo Du, Yulan Sun, Wei Li, Fei Xu, Zhiyu Wang, Kunning Yang, Yun Fan, Baogang Liu, Hongyun Zhao, Ying Hu, Li Jia, Shen Xu, Tienan Yi, Dongqing Lv, Haitao Lan, Mengxia Li, Wenhua Liang, Yongsheng Wang, Hui Yang, Yuming Jia, Yuan Chen, Junguo Lu, Jifeng Feng, Chunling Liu, Ming Zhou, Jianya Zhou, Xianling Liu, Ningning Zhou, Ming He, Xiaorong Dong, Hualin Chen, Yongxing Chen, Haichuan Su, Xiaoling Li, Zhihong Zhang, Lei Yang, Ying Cheng, Likun Chen, Xue Hou, Yu Zhang, Jun Guo, Zhen Wang, Hong Lu, Di Wu, Weineng Feng, Wen Li, Jianan Huang, Yan Wang, Xia Song, Jiewen Peng, Laiyu Liu, Yubiao Guo, Wenting Li, Dongmei Lu, Mingxiu Hu, Zhongmin Maxwell Wang, Baiyong Li, Michelle Xia, Li Zhang*	JAMA	2024;332(7):561-570.	55.0	86
3	Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1/2 and phase 2 trials	Shen Zhao, Ying Cheng, Qiming Wang, Xingya Li, Jun Liao, Jordi Rodon, Xiangjiao Meng, Yongzhong Luo, Zhendong Chen, Wei Wang, Tienan Yi, Yongsheng Li, Yongmei Yin, Huiting Xu, Guohua Yu, Yanjun Mi, Yun Fan, Zev A Wainberg, Xiang Wang, Cuiyun Su, Qitao Yu, Shuzhen Lai, Longhua Sun, Wu Zhuang, Xian Wang, Jiacheng Yang, Yaling Li, Junyou Ge, Jin Li, Li Zhang*, Wenfeng Fang*	Nature Medicine	2025;31(6):1976-1986.	50.0	5
4	BL-B01D1, a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre,	Yuxiang Ma, Yan Huang, Yuanyuan Zhao, Shen Zhao, Jinhui Xue, Yunpeng Yang, Wenfeng Fang, Ye Guo, Yaqian Han, Kunyu Yang, Yongsheng Li, Jun Yang, Zhenming Fu, Gang Chen, Likun Chen, Ningning Zhou, Ting Zhou, Yaxiong Zhang, Huaqiang Zhou, Qianwen Liu, Yi Zhu, Hai Zhu, Sa Xiao, Li Zhang*, Hongyun Zhao*	Lancet Oncology	2024;25(7):901-911.	35.9	53

	phase 1 study					
5	Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study	Caicun Zhou, Sang-We Kim, Thanyanan Reungwetwattana, Jianying Zhou, Yiping Zhang, Jianxing He, Jin-Ji Yang, Ying Cheng, Se-Hoon Lee, Lilian Bu, Tingting Xu, Li Yang, Chao Wang, Ting Liu, Peter N Morcos, You Lu, Li Zhang*	Lancet Respiratory Medicine	2019;7(5):437-446.	32.8	272
6	Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial	Yunpeng Yang, Jianya Zhou, Jianying Zhou, Jifeng Feng, Wu Zhuang, Jianhua Chen, Jun Zhao, Wei Zhong, Yanqiu Zhao, Yiping Zhang, Yong Song, Yi Hu, Zhuang Yu, Youling Gong, Yuan Chen, Feng Ye, Shucui Zhang, Lejie Cao, Yun Fan, Gang Wu, Yubiao Guo, Chengzhi Zhou, Kewei Ma, Jian Fang, Weineng Feng, Yunpeng Liu, Zhendong Zheng, Gaofeng Li, Ning Wu, Wei Song, Xiaoqing Liu, Shijun Zhao, Lieming Ding, Li Mao, Giovanni Selvaggi, Xiaobin Yuan, Yuanqing Fu, Tao Wang, Shanshan Xiao, Li Zhang*	Lancet Respiratory Medicine	2020;8(1):45-53..	32.8	157
7	Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11)	Yunpeng Yang, Zhehai Wang, Jian Fang, Qitao Yu, Baohui Han, Shundong Cang, Gongyan Chen, Xiaodong Mei, Zhixiong Yang, Rui Ma, Minghong Bi, Xiubao Ren, Jianying Zhou, Baolan Li, Yong Song, Jifeng Feng, Juan Li, Zhiyong He, Rui Zhou, Weimin Li, You Lu, Yingyi Wang, Lijun Wang, Nong Yang, Yan Zhang, Zhuang Yu, Yanqiu Zhao, Conghua Xie, Ying Cheng, Hui Zhou, Shuyan Wang, Donglei Zhu, Wen Zhang, Li Zhang*	Journal of Thoracic Oncology	2020;15(10):1636-1646.	20.8	380
8	Updated Overall Survival Data and Predictive Biomarkers of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally	Yunpeng Yang, Jiya Sun, Zhehai Wang, Jian Fang, Qitao Yu, Baohui Han, Shundong Cang, Gongyan Chen, Xiaodong Mei, Zhixiong Yang, Rui Ma, Minghong Bi, Xiubao Ren, Jianying Zhou, Baolan Li, Yong Song, Jifeng Feng, Juan Li, Zhiyong He, Rui Zhou, Weimin Li, You Lu, Hui Zhou, Shuyan	Journal of Thoracic Oncology	2021;16(12):2109-2120.	20.8	117

	Advanced or Metastatic Nonsquamous NSCLC in the Phase 3 ORIENT-11 Study	Wang, Luyao Sun, Oscar Puig, Christoph Mancao, Bo Peng, Wenfeng Fang, Wei Xu, Li Zhang*				
9	First-line sacituzumab tirumotecan with tagitanlimab in advanced non-small-cell lung cancer: a phase 2 trial	Shaodong Hong, Qiming Wang, Ying Cheng, Yongzhong Luo, Xiujuan Qu, Haibo Zhu, Zhenyu Ding, Xingya Li, Lin Wu, Yan Wang, Sheng Hu, Enwen Wang, Anwen Liu, Yuping Sun, Yun Fan, Feng Ye, Kaihua Lu, Jian Fang, Yuping Shen, Xiaoping Jin, Junyou Ge, Li Zhang*, Wenfeng Fang*	Nature Medicine	2025;Online ahead of print.	50.0	0
10	Envonalkib versus crizotinib for treatment-naïve ALK-positive non-small cell lung cancer: a randomized, multicenter, open-label, phase III trial	Yunpeng Yang, Jie Min, Nong Yang, Qitao Yu, Ying Cheng, Yanqiu Zhao, Manxiang Li, Hong Chen, Shou'an Ren, Jianying Zhou, Wu Zhuang, Xintian Qin, Lejie Cao, Yan Yu, Jian Zhang, Jianxing He, Jifeng Feng, Hao Yu, Li Zhang*, Wenfeng Fang*	Signal Transduction and Targeted Therapy	2023;8(1):301.	52.7	25